DrugPatentWatch Database Preview
ACTICLATE Drug Profile
Email this page to a colleague
» See Plans and PricingWhen do Acticlate patents expire, and what generic alternatives are available?
Acticlate is a drug marketed by Almirall and is included in two NDAs.
The generic ingredient in ACTICLATE is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.
US ANDA Litigation and Generic Entry Outlook for Acticlate
A generic version of ACTICLATE was approved as doxycycline hyclate by CARIBE HOLDINGS on November 8th, 1982.
Summary for ACTICLATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 36 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ACTICLATE |
| Drug Sales Revenues: | Drug sales revenues for ACTICLATE |
| DailyMed Link: | ACTICLATE at DailyMed |
Pharmacology for ACTICLATE
| Drug Class | Tetracycline-class Drug |
US Patents and Regulatory Information for ACTICLATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Almirall | ACTICLATE | doxycycline hyclate | TABLET;ORAL | 205931-001 | Jul 25, 2014 | AB | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
| Almirall | ACTICLATE | doxycycline hyclate | TABLET;ORAL | 205931-002 | Jul 25, 2014 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Almirall | ACTICLATE CAP | doxycycline hyclate | CAPSULE;ORAL | 208253-001 | Apr 26, 2016 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
